Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
C1-inhibitor in house dust mite/LPS challenge asthma study
2014-005611-16Phase 4Terminated
- Sponsor
- Amsterdam University Medical Center
- Start
- Feb 2015
- Modality
- Antimicrobial Peptides → Native Peptides → Peptides, Cyclic Peptides → Modified Peptides → Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of C1 inhibitor, human, vancomycin, ciprofloxacin and metronidazole in allergic asthma (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Difference in leukocyte counts in bronchoalveolar lavage fluid. Started Feb 2015; status: terminated.
02
Drugs
C1 inhibitor, humanvancomycinciprofloxacinmetronidazole
03
Conditions
allergic asthma
Beyond the preview
Go deeper on 2014-005611-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-005611-16.